WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 USD
arrow_upward
+0,48%(+0,060) 1 D.
10-16, 16:00:00 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „WXXWY“ įžvalgos...
Atidaryti
12,29 USD
Aukšta
12,56 USD
Žema
12,20 USD
Rinkos kapitalizacija
198,43 mlrd.
Vid. kiekis
61,89 tūkst.
Apimtis
110,85 tūkst.
52 sav. aukšta
14,80 USD
52 sav. žema
7,30 USD
Beta
0,01
Neapmokėtos akcijos
2,06 mlrd.
Darbuotojų skaičius
15 tūkst.
Atidaryti
12,29 USD
Aukšta
12,56 USD
Žema
12,20 USD
Rinkos kapitalizacija
198,43 mlrd.
Vid. kiekis
61,89 tūkst.
Apimtis
110,85 tūkst.
52 sav. aukšta
14,80 USD
52 sav. žema
7,30 USD
Beta
0,01
Neapmokėtos akcijos
2,06 mlrd.
Darbuotojų skaičius
15 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
MarketBeat
·
prieš 31 minutę
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts
The Globe and Mail
·
prieš 35 minutes
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
CryptoPotato
·
prieš 23 minutes
Ripple and XRP Weekly Wrap: Institutional Wins, Nasdaq Debut, and Price Struggles
Yahoo Finance
·
prieš 19 valandų
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profilis
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Apie „Wuxi Biologics Cayman ADR“
Generalinis direktoriusZhisheng Chen
Darbuotojai14,7 tūkst.
Įkurta2010
Pagrindinė būstinė-
Sektorius-
Svetainėwuxibiologics.com